Key Takeaways
- Volume-led quarter, margin squeeze: Q2 volumes rose 17% YoY but finished good prices fell faster than raw material costs, compressing margins by ~2% half year to half year.
- Chinese overcapacity is the structural headwind: Excess Chinese capacity, subdued global agrochemical demand and inventory hangovers are depressing prices across the value chain, with no near-term resolution in sight.
- Monoisopropylamine remains under siege: Chinese import pressure continues unabated; the company has only recently applied for government protection and expects a 9–12 month wait.
- New molecule signals R&D-led pipeline: A second new product from the five-molecule specialty chemicals slate will be commercialized in ~15 months, developed entirely with in-house R&D.
- What to watch next quarter: Progress on the Acetonitrile anti-dumping duty (expected in 4–5 months), any stabilization in agrochemical demand, and whether the DEK plant utilization improvement materializes.
Volume & Margin Dynamics
- Volume growth on a weak base: H1 volumes grew 8–10% YoY and Q2 volumes rose 17% YoY, but management flagged that the comparable quarter last year was weak. Growth came from both domestic and export markets.
- Margin squeeze from price asymmetry: Finished good prices dropped 5–6% while raw material prices fell only 3–4%, creating a ~2% margin compression half year to half year. Management is optimistic on margin improvement but will not sacrifice volume to achieve it.
- Coal costs stable: Coal costs have remained within a +/-10% band across two years; changes in power and fuel costs reflect volume increases, not price movements.
- Ammonia outlook cautious: Management expects some pressure on ammonia prices from the Middle East crisis, with a possible slight bump followed by a drop; procurement is planned month to month.
- Working capital steady: Debtor and creditor days have more or less stabilized; marginal improvement may come as volumes grow, but no significant change is expected.
Kirat Patel: "We are always optimistic that we will try to improve the margin, but we don't want to sacrifice volume because of it. So, our focus will be more volume than margins, but of course at the same time, we try to expand the margins. But it's difficult to say where we will in the end land up."
Chinese Overcapacity & Pricing Pressure
- Capacity, not demand, is the root cause: Pricing pressure is driven primarily by excess Chinese capacity built over the last few years, with Chinese domestic consumption insufficient to absorb it. This pressure cascades across the entire value chain, affecting both the company's products and its customers' products.
- Agrochemical weakness compounds the problem: The global agrochemical and agriculture demand situation remains subdued, and an inventory hangover from earlier cycles is still working through the system.
- European industry under dual pressure: High energy costs for agrochemical and chemical production in Europe, combined with end-user demand for green chemistry and eco-friendly products, is forcing the industry toward new-technology products while existing capacities stay underutilized.
- No timeline for normalization: When asked how long it will take for capacity utilizations to normalize and reasonable margins to return, management declined to give a timeline, noting that even major agrochemical customers are grappling with the same question.
Udipt Agarwal: "I think it is more of a capacity issue right now and a little bit of inventory effect is still hangover, is carrying on."
Product-Specific Updates
- Monoisopropylamine: Pressure from Chinese imports flagged six months ago persists. The company has applied very recently for government protection and hopes to receive it in 9–12 months; until then, pressure will continue. Management did not disclose utilization rates or address whether the old plant could be repurposed for Methylamine.
- Acetonitrile: The oral hearing for anti-dumping duty was completed in October. The next step is plant and costing record investigation by the Ministry of Commerce, followed by Ministry of Finance action taking 3–4 months; a decision is expected in the next 4–5 months. There is room to grow further in this product.
- DEK plant: Utilization has not improved as much as expected, but management believes the worst period is over and is more optimistic on the product now than before. Further utilization improvement is expected going forward.
- Ethylamines: The new plant is very large with plenty of headroom for the next 3–4 years; no pressure on capacities at all. Plants are campaign-based, running at 100% capacity when operating, so there is no meaningful efficiency gain from utilization improvement.
Kirat Patel: "We haven't yet received any protection from the government against the Chinese imports. We have applied very recently for protection, and we hope over the next maybe 9 to 12 months, we will get some protection. But till then the pressure on Monoisopropylamine will continue."
New Product Pipeline & Capex
- Second new molecule commercializing: Out of five molecules in specialty chemicals and allied chemistry announced a couple of years back, this is the second after DEK to be commercialized. The first phase will come online in about 15 months.
- Import-substituted, R&D-developed: The new product is not part of the existing portfolio, is import-substituted, and will be manufactured in Dahej. Technology was developed entirely with in-house R&D; barring initial technologies imported from America, all products launched in the last 35–40 years have been developed with own R&D and engineering.
- Two products on hold: Management is holding back on investments in the next two products, with a decision dependent on market conditions, perhaps in the next six months or a little later.
- Existing capacity sufficient: Barring some small debottlenecking of a couple of products, normalized volume growth for the next 2–3 years can be achieved from existing capacity.
- Land available: Land is available in Dahej and Kurkumbh for at least another 2–3 years with no major issues expected, even after the new project.
Kirat Patel: "It is not part of our existing portfolio. It's a new product. It is going to be manufactured in Dahej as has been stated in the SEBI notice. And... yes, it is an import substituted product."
Revenue Mix & End-Market Trends
- Life sciences dominant, mix shifting: Life sciences remains 65–70% of turnover. Agrochemicals, which are under pressure, are being gradually replaced by pharma within the life sciences division over a longer-term basis.
- Pharma inventory easing: Inventory issues in the pharma sector are easing, providing some demand support.
- Agrochemicals under sustained pressure: The segment continues to face inventory and cost pressure from China at both intermediate and finished levels.
- Capex details withheld: Management will not disclose specific products until they are commercially in the field, noting only that new investments are broadly in the same market region and serve the same kind of customers.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth FY25 | Hope to cross 10% | FY25 |
| Acetonitrile anti-dumping duty | Decision expected after MoC investigation and MoF approval | Next 4–5 months |
| Monoisopropylamine protection | Applied recently; hope to receive government protection | Next 9–12 months |
| New product commercialization | First phase of second new molecule (import-substituted) | ~15 months |
| Existing capacity volume growth | Normalized volume growth achievable from existing capacity | Next 2–3 years |
| Ethylamines capacity headroom | Plenty of headroom; no pressure on capacities | Next 3–4 years |
| Land availability | Sufficient land in Dahej and Kurkumbh | At least 2–3 years |
| Next two pipeline products | Investment decision dependent on market conditions | Perhaps next 6 months or later |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | Not stated |
| Volume growth | 17% YoY for Q2 FY25 |
| H1 FY25 volume growth | 8% to 10% YoY |
| FY25 volume growth guidance | Hope to cross 10% |
| Gross margin movement | Squeezed by about 2% half year to half year, as finished good prices dropped 5%-6% while raw material prices dropped 3%-4% |
| Life sciences revenue share | 65%-70% of turnover |
| Domestic/export revenue split | 80-20 |
| Export share | About 20% annually, 20%-21%; quarter-to-quarter varies 18%-22% |
| Overall capacity utilization | 65% to 70% on average, varies by product |
| Acetonitrile market share | 50% to 55% |
| Acetonitrile plant utilization | Around 60% |
| Indian Acetonitrile market size | ~30,000 tons |
| Indian Ethylamines market size | 25,000 to 30,000 tons |
| Coal cost | Rs. 9,000 to Rs. 10,000 per metric ton, stable across two years (+/-10%) |
| FY25 capex outlook | ₹80 to 100 crores |
| FY26 capex outlook | ₹100 to 120 crores |
| New product capex timeline | First phase in about 15 months; potential debottleneck/expansion within next 3-4 years |